Show simple item record

dc.contributor.authorAdriaenssens, Niels
dc.contributor.authorCoenen, Samuel
dc.contributor.authorMuller, Arno
dc.contributor.authorVankerckhoven, Vanessa
dc.contributor.authorGoossens, Herman
dc.contributor.authorKristinsson, KG
dc.contributor.authorESAC Project Group
dc.date.accessioned2012-05-03T11:11:16Z
dc.date.available2012-05-03T11:11:16Z
dc.date.issued2010-04
dc.date.submitted2012-05-03
dc.identifier.citationJ. Antimicrob. Chemother. 2010;65(4):769-74en_GB
dc.identifier.issn1460-2091
dc.identifier.pmid20142264
dc.identifier.doi10.1093/jac/dkq023
dc.identifier.urihttp://hdl.handle.net/2336/221842
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden_GB
dc.description.abstractOBJECTIVES: To assess the total outpatient systemic antimycotic and antifungal use in Europe, and to identify the antimycotic and antifungal substances most commonly used. METHODS: Within ESAC (www.esac.ua.ac.be), using the anatomical therapeutic chemical (ATC) and defined daily dose (DDD) classification, data on outpatient use of all 14 antimycotics (12) and antifungals (2) for systemic use (ATC J02 and D01B, respectively), aggregated at the level of the active substance, were collected for 2007. Use was expressed in DDD (WHO ATC/DDD, version 2008) per 1000 inhabitants per day (DID). Only countries for which data on both J02 and D01B use were available were included in the analysis. RESULTS: In 20 European countries (data for Cyprus and Estonia include hospital use), total outpatient systemic antimycotic and antifungal use varied by a factor of 6.7 between the country with the highest (3.03 DID in Belgium) and the country with the lowest (0.45 in Croatia) use. Terbinafine, ketoconazole, itraconazole and fluconazole represented >94% of the total outpatient antimycotic and antifungal use in all countries. Terbinafine use represented >50% of the total systemic antimycotic and antifungal use in 16 out of 20 countries (not in Croatia, Italy, Luxembourg and Bulgaria). CONCLUSIONS: We present for the first time a standardized and validated data set of outpatient systemic antimycotic and antifungal use in Europe. Our study demonstrates a variation of antimycotic and antifungal use in Europe, as striking as that of antibiotic use. The ESAC data facilitate the auditing of antimycotic and antifungal prescribing, and the evaluation of the implementation of guidelines and public health policies to promote their judicious use.
dc.language.isoenen
dc.publisherOxford University Pressen_GB
dc.relation.urlhttp://dx.doi.org/10.1093/jac/dkq023en_GB
dc.rightsArchived with thanks to The Journal of antimicrobial chemotherapyen_GB
dc.subject.meshAmbulatory Careen_GB
dc.subject.meshAntifungal Agentsen_GB
dc.subject.meshDrug Utilizationen_GB
dc.subject.meshEuropeen_GB
dc.subject.meshHumansen_GB
dc.titleEuropean Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europeen
dc.typeArticleen
dc.contributor.departmentLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium. Niels.Adriaenssens@ua.ac.been_GB
dc.identifier.journalJournal of antimicrobial chemotherapyen_GB
html.description.abstractOBJECTIVES: To assess the total outpatient systemic antimycotic and antifungal use in Europe, and to identify the antimycotic and antifungal substances most commonly used. METHODS: Within ESAC (www.esac.ua.ac.be), using the anatomical therapeutic chemical (ATC) and defined daily dose (DDD) classification, data on outpatient use of all 14 antimycotics (12) and antifungals (2) for systemic use (ATC J02 and D01B, respectively), aggregated at the level of the active substance, were collected for 2007. Use was expressed in DDD (WHO ATC/DDD, version 2008) per 1000 inhabitants per day (DID). Only countries for which data on both J02 and D01B use were available were included in the analysis. RESULTS: In 20 European countries (data for Cyprus and Estonia include hospital use), total outpatient systemic antimycotic and antifungal use varied by a factor of 6.7 between the country with the highest (3.03 DID in Belgium) and the country with the lowest (0.45 in Croatia) use. Terbinafine, ketoconazole, itraconazole and fluconazole represented >94% of the total outpatient antimycotic and antifungal use in all countries. Terbinafine use represented >50% of the total systemic antimycotic and antifungal use in 16 out of 20 countries (not in Croatia, Italy, Luxembourg and Bulgaria). CONCLUSIONS: We present for the first time a standardized and validated data set of outpatient systemic antimycotic and antifungal use in Europe. Our study demonstrates a variation of antimycotic and antifungal use in Europe, as striking as that of antibiotic use. The ESAC data facilitate the auditing of antimycotic and antifungal prescribing, and the evaluation of the implementation of guidelines and public health policies to promote their judicious use.


This item appears in the following Collection(s)

Show simple item record